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Letters to the Editor
1080Stage of portal vein thrombosisinterest with respect to this manuscript.To the Editor:
Similar to previous recommendations [1–3], a stage-dependent
therapeutic strategy of non-malignant and non-cirrhotic portal
vein thrombosis (PVT) is advocated in the recent Baveno V con-
sensus [4]. At recent or acute stage of PVT, the predominant goals
of treatment are to maximize the rate of portal vein recanaliza-
tion and to prevent thrombus extension upstream into the supe-
rior mesenteric vein and its possible secondary intestinal
infarction. At the old or chronic stage, the primary therapeutic
objectives are shifted to the prevention and treatment of variceal
bleeding and management of portal biliopathy. Despite the fact
that this uniform therapeutic strategy is widely approved, no
clear deﬁnition for staging of PVT has been postulated until
now. Thus, the heterogeneity of the criteria might greatly pre-
clude the standardization of the above-mentioned therapeutic
strategy and the further evaluation of the outcomes.
It has been widely accepted that the formation of portal caver-
noma has been considered the ‘‘tipping point’’ between acute and
chronic PVT. Once portal cavernoma is detected, the patients are
regarded as having entered the chronic stage. However, this does
not completely fall in line with our clinical practice. Fig. 1 dem-
onstrates the transverse computed tomography (CT) images
obtained at the hilum in one patient who was admitted to our
department due to a recent onset of abdominal pain in the
absence of complications of portal hypertension. Contrast-
enhanced CT scans showed cavernous vessels around the throm-
bosed portion of the main portal vein (Fig. 1, A). This ﬁnding
suggests that PVT might have been at the chronic phase accord-
ing to the prior criteria. Conversely, non-enhanced CT scans
showed a high intraluminal density within the portal vein
(Fig. 1, panel B), which was strongly suggestive of a fresh throm-Journal of Hepatology 20bus because the protein fraction of hemoglobin in the clot
resulted in the elevated CT attenuation value. From our perspec-
tive, despite the detection of portal cavernoma, this group of
patients should be classiﬁed into the acute stage and treated with
anticoagulation and thrombolysis to resolve abdominal symp-
toms and recanalize the thrombosed portal vein.
Both experimental and clinical observations have indicated
that the cavernous transformation could rapidly develop within
a few days after the formation of fresh PVT [5,6]. Despite the
fact that the compensatory mechanism of collateral circulation
is very helpful to drain intestinal congested blood and maintain
total hepatic blood ﬂow [7], thrombus progression and exten-
sion still go on, which may result in progressive abdominal
presentations in some patients with PVT. Accordingly, we pos-
tulated that the therapeutic strategy of the early period of cav-
ernous transformation might be similar to that of the acute
stage.
In the end, based on our previous observations [8,9], we
attempted to draw an elementary schematic diagram demon-
strating the possible course of portal vein thrombosis and the
progression of symptoms (Fig. 2). But it should be noted that
the natural history of EHPVO is a complex and dynamic process,
and thus this new framework needs to be further improved in
many aspects, such as clariﬁcation of the role of thrombotic
recurrence and the prognostic signiﬁcance of ascites.
Conﬂict of interest
The authors who have taken part in this study declared that they
do not have anything to disclose regarding funding or conﬂict of11 vol. 54 j 1079–1083
Acknowledgments
We are greatly indebted to Wengang Guo and Jing Niu for their
efforts regarding proper preservation of all imaging data.
References
[1] de Franchis R. Evolving consensus in portal hypertension. Report of the
Baveno IV consensus workshop on methodology of diagnosis and therapy in
portal hypertension. J Hepatol 2005;43:167–176.
[2] DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatol-
ogy 2009;49:1729–1764.
[3] Sarin SK, Sollano JD, Chawla YK, Amarapurkar D, Hamid S, Hashizume M, et al.
Consensus on extra-hepatic portal vein obstruction. Liver Int 2006;26:512–519.
[4] de Franchis R. Revising consensus in portal hypertension: Report of the
Baveno V consensus workshop on methodology of diagnosis and therapy in
portal hypertension. J Hepatol 2010;53:762–768.
[5] Ide T, Ohno Y, Nakanuma Y, Kanematsu T. Early development of cavernoma-
tous vasculatures in portal venous thrombosis: morphometric kinetics in
rabbit model. Hepatol Res 2003;27:136–142.
[6] De Gaetano AM, Lafortune M, Patriquin H, De Franco A, Aubin B, Paradis K.
Cavernous transformation of the portal vein: patterns of intrahepatic and
Fig. 1. Axial contrast-enhanced and non-enhanced computed tomography (CT) scans obtained at the hilum in a patient with recent portal vein thrombosis. (A)
Enhanced CT scan demonstrated the absence of luminal enhancement within main portal vein and superior mesenteric vein (black arrows) and development of collateral
vessels. (B) Non-enhanced CT scan demonstrated a high density within main portal vein and superior mesenteric vein (white arrows).
Symptomatic portal hypertension, portal biliopathy, 
growth retardation, hepatic dysfunction, and etc.
Intestinal ischemia, ileus,
intestinal infarction, shock, and etc.
Portal vein recanalization
Prevention and treatment of variceal bleeding
Management of portal biliopathy
Prevention of thrombotic recurrence in patients with prothrombotic disorders
Treatment of recurrent thrombotic events
SymptomaticSymptomatic Asymptomatic
No varices Bleeding varicesOccurrence and progression
of varices
Partial or 
complete EHPVO
Acute stage
Partial 
or complete EHPVO
Portal cavernoma
Complete EHPVO
Chronic stage
Portal vein obliteration
or fibrotic cord
Chronic stage
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Revising consensus in portal hypertension
Report of the Baveno V Consensus Workshop on methodology of
diagnosis and therapy in Portal Hypertension
This is a reply to the Letter to the Editor by Qi et al.
We read with great interest the letter by Dr. Qi et al. [1]. We do
agree with them that, at times, it is difﬁcult to make a precise
diagnosis of acute and chronic portal vein thrombosis on the
basis of contrast enhanced CT alone, especially if it is in the tran-
sition period and the disease is evolving. In making a proper diag-
nosis, one needs to take into account the natural history,
including the rapidity of development of the thrombus, the
appearance of symptoms, the extent of the thrombosis, and the
development of complications. Previous and present attempts
by the same group of workers [1,2] and by others [3] have only
looked at the degree and duration of the development of PVT.
The ﬁgures enclosed with the present communication [1] clearly
show opening-up of various porto–porto collateral channels and
development of a cavernoma. Of course, it is not easy to hypoth-
esize the age of the cavernoma, in the absence of full clinical
details. A Doppler ﬂow image would have been quite helpful to
determine the nature of the thrombosis and the degree of
involvement of splanchnic circulation. A second look at the con-
sensus statements of the Baveno V [4] may help clarify the situ-
ation in the patient under consideration. A recent thrombosis is
deﬁned as non-enhancing material within the portal vein (PV)
with increased hepatic enhancement in the arterial phase. It is
important to note that the recommendations are that a CT/MR
angiography is more helpful to determine the nature of the
thrombosis. In the given case, the collaterals are already
enhanced in the CT images after the contrast injection. There is,
however, a non-enhanced material also seen inside the PV, sug-
gestive of a possible recent thrombosis.
It is well known that in patients with EHPVO, thrombosis
could be an ongoing process, and both clinical situations could
co-exist. However, once the cavernoma forms, there remains no
doubt about the process being chronic. Because of these reasons,
the proposed nomenclature by Dr. Qi et al. of partial and com-
plete in both acute and chronic stages seems a bit empirical. All
these issues were discussed in the Baveno meeting. Further, the
Baveno statement clearly mentions the role of both Color Doppler
ultrasound and the contrast enhanced US to conﬁrm the recent
thrombosis and differentiate it from the chronic thrombosis; a
yard-stick, which was not followed by the authors [1].
In the Baveno V conference, a detailed discussion on different
clinical scenarios of EHPVO was presented by us and was then
deliberated at length by global experts. A comprehensive consen-
sus classiﬁcation was ﬁnally approved (manuscript under prepa-
ration). The consensus statement reads ‘‘Baveno classiﬁcation of
EHPVO: This classiﬁcation utilizes ﬁve main characteristics of
portal vein obstruction, namely: the site of obstruction (trunk
or branches), the clinical presentation (recent or chronic), nature
of underlying liver disease, the degree of occlusion and the extent
of involvement’’. Such a classiﬁcation is needed and once pub-
lished would hopefully be found useful for new studies, as it will
bring uniformity in reporting the results and comparing the
outcome.
We are delighted that Dr. Han and colleagues have looked into
the various complications of chronic EHPVO. In fact, several large
series have reported the long-term outcome of portal vein occlu-
sion. Development of portal biliopathy, progressive hepatic dys-
function as a result of chronic deprivation of blood ﬂow and
growth factors, and growth retardation (if the portal vein occlu-
sion has occurred in pre-pubertal age) are well known complica-
tions of chronic EHPVO [5]. These complications highlight the
need for early detection and intervention in such patients. It is
well accepted that the outcome of long standing portal biliopa-
thy, an entity identiﬁed nearly 20 years ago, remains dismal.
Endoscopic interventions and even surgical shunts do not fully
reverse the process [6,7]. It is associated with high morbidity
and mortality. Similarly, growth retardation is commonly seen
in nearly 30–50% of the subjects [8]. At the Baveno V meeting,
management of these complications was discussed. It was pro-
posed that Rex bypass (mesenterico-left portal bypass) in chil-
dren with EHPVO [9] has been shown to reverse complications
associated with EHPVO including retardation of growth
and development, minimal encephalopathy, coagulopathy, and
hypersplenism. It prevents portal hypertensive bleeding
and may prevent development of biliopathy. Of course, proper
patient selection and expertise would be required for optimal
outcome. Placement of TIPS stents and liver transplantation could
also be occasionally helpful. EHPVO remains a challenge for
hepatologists and we do hope that with a better understanding
of the pathophysiology and mechanisms of PV thrombosis, we
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